Cambria Hotels opens property in California's central coast
The 132-room boutique-style Cambria Hotel Templeton-Paso Robles hotel, franchised by Choice Hotels International, will be managed by Pacifica Hotels.
Pacifica Hotels president Scott Roby said: 'We are thrilled to open our doors in Templeton and bring the Cambria experience to this vibrant and rapidly growing destination.
'This new hotel is designed for travellers who seek authentic local experiences at a great price without compromising on premium amenities and comfort.'
The hotel, which had a soft opening last month, is now fully operational and offers 12 electric vehicle (EV) charging stations and solar panels, highlighting its commitment to sustainability.
Cambria Hotel Templeton is designed to provide contemporary accommodations. Available amenities include a full-service restaurant and bar, resort pool, spa, cabanas, event lawn, outdoor bar, and firepits.
The property is strategically located close to Paso Robles and San Luis Obispo. In addition, more than 200 wineries, craft breweries, and coastal drives are within a short drive away.
In November 2024, Choice Hotels International expanded the Cambria Hotels brand with the inauguration of three new properties across the US.
These include Cambria Hotel El Centro in Imperial, California; Cambria Hotel Pigeon Forge in Tennessee; and Cambria Hotel Spokane Airport in Washington.
"Cambria Hotels opens property in California's central coast" was originally created and published by Hotel Management Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Smithfield Lifts Full-Year Outlook as Hog Unit Returns to Profit
(Bloomberg) -- Smithfield Foods Inc., the largest pork supplier in the US, raised its full-year profit expectations as a rebound in its hog business counterbalances the impact of tariffs. US hog prices have risen this year amid tight supplies, helping lift profits for suppliers already benefiting from low feed costs. Virginia-based Smithfield has streamlined its own pig production to focus on its more profitable packaged food business, shutting down unprofitable farms and transferring part of its farming operations to a new venture. Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion New York Warns of $34 Billion Budget Hole, Biggest Since 2009 Crisis To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' Chicago Schools' Bond Penalty Widens as $734 Million Gap Looms A New Stage for the Theater That Gave America Shakespeare in the Park The manufacturer of Farmland bacon and Farmer John sausages has been able to minimize the impact of China tariffs on US pork exports by tapping alternative markets, while subsequently resuming shipments to the Asian nation, according to Chief Executive Officer Charles Shane Smith. 'While we are not immune to the impacts of tariffs, we have built flexibility into our system and established multiple outlets for our fresh pork products,' Smith said during a conference call with analysts. The return to profit for hog operations was a major driver for the company's improved outlook. Smithfield is now projecting adjusted operating profit to range from $1.15 billion to $1.35 billion in 2025, an increase of $50 million at the midpoint from the prior guidance, according to a Tuesday statement. Shares of Smithfield dropped 0.7% as of 10:19 a.m. in New York, extending a retreat after reaching an all-time high last week. (Updates share move.) Why It's Actually a Good Time to Buy a House, According to a Zillow Economist Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan The Social Media Trend Machine Is Spitting Out Weirder and Weirder Results Klarna Cashed In on 'Buy Now, Pay Later.' Now It Wants to Be a Bank The Game Starts at 8. The Robbery Starts at 8:01 ©2025 Bloomberg L.P.
Yahoo
6 minutes ago
- Yahoo
IonQ (IONQ) Climbs 7.38% as US Pension Fund Raises Exposure to Quantum Computing
We recently published . IonQ, Inc. (NYSE:IONQ) is one of the best-performing stocks on Monday. IonQ grew its share prices by 7.38 percent on Monday to close at $44.94 apiece as investor sentiment was bolstered by news that a huge public pension fund in the US increased its exposure to quantum computing stocks as part of its portfolio rebalancing. According to reports over the weekend, the New Jersey State Pension Fund divested its stake in Alibaba Group Holding Ltd. (BABA) and gobbled up shares in quantum computing stocks, namely IonQ, Inc. (NYSE:IONQ), D-Wave Quantum Inc. (NYSE:QBTS), and Rigetti Computing Inc. (NASDAQ:RGTI). The move sparked buying appetite across the quantum computing sector, given the fund's reputation as one of the largest fund management agencies in the US. In other news, IonQ, Inc. (NYSE:IONQ) filed for a prospectus on behalf of several existing shareholders for the sale of more than 13 million IONQ common shares. IonQ, Inc. (NYSE:IONQ) said it will not receive any proceeds from the proposed sale. While we acknowledge the potential of IONQ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
6 minutes ago
- Yahoo
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
